Lavipharm

Lavipharm CROIC

The Cash Return on Invested Capital (CROIC) of Lavipharm (LAVI.AT) as of Oct 29, 2026 is 2.48 %. In the previous year, Cash Return on Invested Capital (CROIC) was -5.59 % — a change of -144.38% (higher).

CROIC

2.48 %

YoY

-144.38%

Last updated:

Cash Return on Invested Capital (CROIC) of Lavipharm is 2025 2.48 % . Cash Return on Invested Capital (CROIC) of Lavipharm was 2024 -5.59 % . It decreases by -144.38% higher compared to the previous year.

The Lavipharm CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
1.89 EUR
Jan 1, 2019
1.84 EUR
Jan 1, 2020
5.75 EUR
Jan 1, 2021
7.03 EUR
Jan 1, 2022
-41.69 EUR
Jan 1, 2023
-4.77 EUR
Jan 1, 2024
-5.59 EUR
Jan 1, 2025
2.48 EUR
The Lavipharm CROIC history
YEARCROICYoY
2.48 %-144.38%
-5.59 %+17.22%
-4.77 %-88.57%
-41.69 %-692.74%
7.03 %+22.29%
5.75 %+213.32%
1.84 %-3.07%
1.89 %-65.60%
5.50 %+395.33%
1.11 %-7.54%
1.20 %-55.64%
2.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

Cash Return on Invested Capital (CROIC) of Lavipharm is 2.48 % in 2025.

Cash Return on Invested Capital (CROIC) of Lavipharm changed from -5.59 % to 2.48 %, representing a -144.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Lavipharm since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Lavipharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lavipharm

All Key Metrics — Lavipharm